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Once unimaginable, fertility management is now a nationally established part of cancer care in insti-
tutions, from academic centers to community hospitals to private practices. Over the last two decades,
advances in medicine and reproductive science have made it possible for men, women and children to be
connected with an oncofertility specialist or offered fertility preservation soon after a cancer diagnosis.
The Oncofertility Consortium’s National Physicians Cooperative is a large-scale effort to engage physi-
cians across disciplines – oncology, urology, obstetrics and gynecology, reproductive endocrinology, and
behavioral health – in clinical and research activities to enable significant progress in providing fertility
preservation options to children and adults. Here, we review the structure and function of the National
Physicians Cooperative and identify next steps.
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In 2007, the Oncofertility Consortium (OC) was established with the support of an NIH grant to address fertility
concerns, including impact on quality of life, for children and patients of reproductive age diagnosed with cancer [1].
The original focus of the OC was female fertility preservation (FP) because at the time options were limited. To that
end, initial clinical efforts were placed on offering ovarian tissue cryopreservation (OTC) to women and children.
The OC has since expanded to become a global, interdisciplinary, and interprofessional network of specialists and
scientists who explore the relationships between health, disease, survivorship and FP in children and patients of
reproductive age [1–5]. To translate bench advances to clinical practice and to develop necessary interactions between
practitioners, the OC developed the National Physicians Cooperative (NPC).
NPC administration
The NPC is a nationwide network of institutions dedicated to preserving the fertility of patients with cancer
and other conditions whose progression or treatment may impair fertility. The NPC was originally comprised of
four core centers: Northwestern University, University of Pennsylvania, Oregon National Primate Research Center
and University of California, San Diego [6], but has since expanded to include 83 institutions within the USA
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(Figure 1). In addition to the NPC, the OC has expanded to include the Oncofertility Global Partners Network,
with 91 institutions in 37 countries [7]. The NPC is managed by an administrative team that provides guidance
on developing a successful FP program and facilitates review of OTC and testicular tissue cryopreservation (TTC)
protocols by the site’s institutional review board (IRB) (Table 1). NPC membership is open to any institution with
providers who care for children, adolescents and/or adults of childbearing age whose disease or its treatment may
impair fertility. Participants at NPC member institutions include oncologists, surgeons, endocrinologists, urologists,
gynecologists, rheumatologists, mental health professionals, geneticists, embryologists, patient navigators, research
coordinators, social workers, nurses, nurse practitioners, physician assistants and trainees in both adult and pediatric
populations. Due to the diverse nature of the oncofertility community, specialized subcommittees were formed at
the urging of our members. All NPC participants are invited to join subcommittees focused on specific interest areas,
including basic science, male oncofertility, pediatrics, education, and gender and sex diversity. These subcommittees
facilitate interactions between individuals at NPC member institutions, provide participants with a forum to discuss
challenges, develop research collaborations, identify best practices with highly engaged peers and have developed
numerous products that expand the reach of the OC to improve patient and provider education, ultimately leading
to improved patient care and outcomes (Table 1). These materials are available for patient and provider education
through Reprotopia (a K-gray reproductive health education website); SaveMyFertility (an informational website
providing education and guidance to patients, parents and providers); and the patient navigator website (a site
where patients and providers can walk through available FP options) (Table 2). To supplement online written
materials, the OC maintains a library of video content on the OC website and YouTube channel including archived
Oncofertility Conference presentations, Virtual Grand Rounds and laboratory training materials.
All NPC member institutions participate in a robust exchange of research initiatives, best practices and exemplary
patient care and are advised to follow American Society of Clinical Oncology (ASCO) and National Comprehensive
Cancer Network (NCCN) guidelines for informing patients of fertility risk and the range of FP options available
to them based on age, time-to-treatment, medical condition and personal preferences. Standard FP options include
pelvic shielding, egg and embryo banking, and ovarian transposition for adult females; sperm banking, testicular
sperm extraction, and testis shielding for adult males; ovarian shielding and transposition for adolescent females;
and testis shielding for adolescent males. Experimental procedures must be submitted to the institution’s IRB for
Figure 1. States with National Physicians Cooperative member institutions are shown in purple, demonstrating the
geographical reach of the Oncofertility Consortium.
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Table 1. Oncofertility Consortium-National Physicians Cooperative products created from 2007 to 2017 to
address the unmet needs of Oncofertility Consortium stakeholders.
Year Product Source Type
2007 Ovarian tissue slow-freeze media and holding media Sage/Origio Laboratory media
2007 Ovarian tissue cryopreservation protocol and consent
documents
Oncofertility Consortium IRB document
2007 Ovarian tissue cryopreservation users manual Oncofertility Consortium Training resource
2007 Oncofertility: fertility preservation for cancer survivors Springer Textbook
2009 Save My Fertility iPhone App Apple Educational material
2009 Preservation of fertility in patients with cancer New England Journal of Medicine Publication
2010 Oncofertility: ethical, legal, social and medical perspectives Springer Textbook
2012 Oncofertility medical practice Springer Textbook
2012 Adolescent fertility values clarification tool Oncofertility Consortium and Moffitt Cancer Center Training resource
2013 Testicular tissue cryopreservation protocol Oncofertility Consortium and University of Pittsburgh IRB document
2013 Fertility preservation Yen and Jaffe’s Reproductive Endocrinology, 7th Edition Book chapter
2014 Ovarian tissue dissection video Oncofertility Consortium Training resource
2014 Fertility preservation preferences and perspectives among
adult male survivors of pediatric cancer and their parents
Journal of Adolescent and Young Adult Oncology Publication
2014 Oncofertility communication Springer Textbook
2014 Prospective study of depression and anxiety in female
fertility preservation and infertility patients
Fertility and Sterility Publication
2015 OC-SHARES Oncofertility Consortium Training resource
2015 Understanding fertility in young female cancer patients Journal of Women’s Health Publication
2015 Pediatric and teen ovarian tissue removed for
cryopreservation contains follicles irrespective of age,
disease diagnosis, treatment history and
specimen-processing methods
Journal of Adolescent Young Adult Oncology Publication
2015 Impact of fertility concerns on tamoxifen initiation and
persistence
Journal of the National Cancer Institute Publication
2015 Oncofertility: a grand collaboration between reproductive
medicine and oncology
Reproduction Publication
2015 In vitro follicle growth supports human oocyte meiotic
maturation
Scientific Reports – Nature Publication
2016 Good manufacturing practice requirements for the
production of tissue vitrification and warming and recovery
kits for clinical research
J ournal of Assisted Reproductive Genetics Publication
2016 Proceedings of the working group session on fertility
preservation with gender and sex diversity
Transgender Health Publication
2016 Oncologists’ role in patient fertility care: a call to action JAMA Oncology Publication
2016 Fellow education day curriculum Oncofertility Consortium Training resource
2017 Updated provider and patient pocket guides SaveMyFertility.org Educational material
2017 Pediatric and adolescent oncofertility Springer Textbook
2017 Fertility preservation and restoration for patients with
complex medical conditions
Springer Textbook
2017 New you, that’s who: puberty Oncofertility Consortium Educational material
2017 New you, that’s who: menstruation Oncofertility Consortium Educational material
2017 New you, that’s who: anatomy Oncofertility Consortium Educational material
2017 The ethics of fertility preservation for pediatric patients
with differences (disorders) of sex development
Journal of the Endocrine Society Publication
2017 Retrospective OTC protocol NPC-PIN IRB document
2017 ASRM e-learning training modules ASRM and Oncofertility Consortium Educational material
2017 Fertility preservation training for obstetrics and gynecology
fellows: a highly desired but non-standardized experience
Fertility Research and Practice Publication
2017 Practices and attitudes regarding women undergoing
fertility preservation: a survey of the National Physicians
Cooperative
Journal of Adolescent Young Adult Oncology Publication
ASRM: American Society for Reproductive Medicine; IRB: Institutional review board; OC-SHARES: Oncofertility Consortium-Scientific Help Agreement for Research Endeavors;
OTC: Ovarian tissue cryopreservation.
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Table 1. Oncofertility Consortium-National Physicians Cooperative products created from 2007 to 2017 to
address the unmet needs of Oncofertility Consortium stakeholders (cont.).
Year Product Source Type
2017 ‘Tissue papers’ from organ-specific decellularized
extracellular matrices
Advanced Functional Materials Publication
2017 Fertility lost-fertility found: narratives from the leading
edge of oncofertility
Narrative Inquiry in Bioethics Publication
2017 ‘When you’re a baby you don’t have puberty’:
understanding of puberty and human reproduction in late
childhood and early adolescence
Journal of Early Adolescence Publication
2017 Oncofertility program implementation increases access to
fertility preservation options and assisted reproductive
procedures for breast cancer patients
Journal of Surgical Oncology Publication
2018 Ovarian tissue cryopreservation in young females through
the Oncofertility Consortium’s National Physicians
Cooperative
Future Oncology Publication
2018 Fertility preservation Yen and Jaffe’s Reproductive Endocrinology, 8th Edition Book chapter
ASRM: American Society for Reproductive Medicine; IRB: Institutional review board; OC-SHARES: Oncofertility Consortium-Scientific Help Agreement for Research Endeavors;
OTC: Ovarian tissue cryopreservation.
review and research determination, including any FP procedure deemed experimental by the American Society for
Reproductive Medicine (ASRM), such as OTC and TTC [8,9]. Some NPC member institutions are not in a position
to offer OTC or TTC to patients due to administrative constraints, lack of infrastructure or tissue expertise, or
patient volume, and instead elect to participate in other ways such as survey studies and product development [10].
Institutions without OTC or TTC protocols on-site are able to quickly obtain referrals for their patients at nearby
institutions with expanded FP services by contacting the OC’s national FP hotline, the FERTline.
Strategies to improve reproductive outcomes for patients
While the NPC administrative team facilitates development of educational materials and dissemination of research
achievements, the individual participants at NPC member institutions are direct points of contact with patients
and many are leaders in translational research. NPC investigators can access rare human reproductive tissues for
further research to explore and expand the reproductive options of patients. Leaders from the four core NPC sites
established a comprehensive framework for a national OTC protocol. The initial framework included a letter of
agreement for membership, IRB templates, creation of a slow-freeze media for OTC and a business partnership
with a company (Origio) to provide high-quality manufacturing facilities for the specialized OTC media. This
framework enabled distribution of OTC media to approved sites, agreements with ReproTech (a US company
that provides long-term storage of reproductive tissue) to store OTC or TTC tissue, partnership with Memorial
Blood Centers (a US FDA-licensed and compliant scientific laboratory) to perform infectious disease testing, and
a pathway for cataloging research tissue and clinical data. Each process is outlined in detail within the OTC User
Manual on the OC website (Table 1). OTC- and TTC-specific materials are publicly available to ensure that any
institution interested in performing OTC or TTC, regardless of affiliation with the NPC, can utilize OC-developed
protocols.
Between 2007 and 2017, 420 participants underwent OTC at an NPC member institution under an IRB-
approved protocol. Patients could elect to freeze 100% of their ovarian tissue for their own future use or keep 80%
of the removed ovarian tissue for future use and donate 20% of the remaining tissue to the OC-NPC Repository. Ten
percent of the research tissue was formalin fixed and paraffin embedded to generate a fixed research tissue archive,
and the remaining research tissue was either used fresh or cryopreserved for future study. The actual amount of tissue
removed from each patient ranged from a small biopsy to a whole ovary, depending on site- and patient-specific
variables and patient-provider decisioning. The OC-NPC Repository is accessible to NPC researchers through
a formal tissue access request as part of the Oncofertility Consortium-Scientific Help Agreement for Research
Endeavors (OC-SHARES; Table 1).
Scientific objectives
Research using the OC-NPC Repository has led to new knowledge and breakthrough technologies that have the
potential to provide new FP and restoration options for young cancer patients [11]. On the basic science side,
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Table 2. Enduring educational resources developed through the Oncofertility Consortium and National
Physicians Cooperative for ongoing use and reference throughout the Oncofertility Consortium community.
Educational resource Summary
Oncofertility Consortium website
www.oncofertility.northwestern.edu
Authoritative resource for professionals in reproductive medicine, reproductive
health research, oncology, biomechanics, material science, social sciences, bioethics,
religion, policy research and educational sciences. This site provides continually
updated content to expand current knowledge research, clinical practice and
training in a wide spectrum of topics and issues
Oncofertility conference presentations and virtual grand rounds
https://oncofertility.northwestern.edu/media
The OC maintains video archives of all lectures at the Annual Oncofertility
Conference and Virtual Grand Rounds. These presentations, given by domestic and
international leaders in the field are hosted on the OC website with accompanying
slides for easy review
Introduction to reproduction
www.coursera.org/learn/reproductive-health
The objective of this MOOC is to ensure an understanding of reproductive health
and not confuse reproduction with sex. This course examines reproduction through
a biological and scientific lens in an interactive format
ASRM principles of fertility preservation for reproductive
healthcare providers certificate course
https:
//store.asrm.org/Default.aspx?TabID=1356&productId=2777391
Developed in collaboration with OC leaders, this e-learning module is free to
both ASRM members and nonmembers and covers the topics of:
• Overview of the initial fertility preservation consultation
• Toxicity of chemotherapy and radiation treatment considerations for common
conditions
• Controlled ovarian stimulation in fertility preservation
• Mature oocyte cryopreservation
• Conservative treatment for gynecologic malignancies
• Use of GnRH agonists for fertility preservation
• Survivorship
• Fertility preservation in male patients
• Sperm cryopreservation methodology
• Fertility preservation and reproduction in patients facing gonadotoxic therapies
• Posthumous collection and use of reproductive tissues
Oncofertility books
www.woodrufflab.org/oncofertility-books
The OC, with substantial input from the NPC, has published six books on
oncofertility covering the overall scope of reproductive health and considerations
for cancer patients and those with non-malignant conditions whose disease or
treatment may affect fertility. Titles include:
• Oncofertility: fertility preservation for cancer survivors
• Oncofertility: ethical, legal, social, and medical perspectives
• Oncofertility medical practice: clinical issues and implementation
• Oncofertility communication: sharing information and building relationships
across disciplines
• Pediatric and adolescent oncofertility: best practices and emerging technologies
• Fertility preservation and restoration for patients with complex medical
conditions
SaveMyFertility
www.savemyfertility.org
A resource for adult cancer patients and the parents of children with cancer who
want to learn more about fertility preservation before and during cancer treatment
and protecting their hormonal health after cancer treatment. This website also
provides guidance to clinicians and other healthcare providers on how to discuss
fertility and hormonal health with patients, survivors and families
Reprotopia
www.reprotopia.northwestern.edu/
This website is dedicated to providing authoritative reproductive health education
to individuals of all ages – ‘From K to Gray’. The OC and its partners have created a
variety of useful websites, courses and other education tools to educate the public
about the importance of reproduction and science. Reprotopia packages all of
these web materials into one easy-to-navigate website
Repropedia
www.repropedia.org
This reproductive dictionary was created by an international team of scientists and
clinicians and includes an API, allowing it to be built into other websites to
supplement information and clarify unclear terms. Repropedia contains more than
500 reproductive health terms and biology information
Patient navigator for fertility preservation
http://preservefertility.northwestern.edu/
This website provides patients with a concise, easy to understand summary of
available fertility preservation options at various stages of diagnosis, treatment and
survivorship
New you, that’s who
www.reprotopia.northwestern.edu/projects/new-you-that’s-who
This video project is targeted toward children 10–14 years of age to teach the basics
of reproductive health. It uses proper, anatomically correct terms to cover the topics
of puberty, anatomy and the menstrual cycle along with songs and animations to
provide easy-to-understand information. It helps parents, guardians and teachers
teach children about the fundamental characteristics of the human body and
reproductive health
API: Application programming interface; ASRM: American Society for Reproductive Medicine; MOOC: Massive open online course; NPC: National Physicians Cooperative;
OC: Oncofertility Consortium.
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OC researchers are developing new ways to grow and mature follicles ex vivo and engineer novel biomaterials for
ovarian tissue transplantation to restore reproductive and/or endocrine function [11–14]. Research using human
tissue has led to our understanding of how best to transport ovarian tissue and how to cryopreserve tissue and
individual follicles [12,13]. Moreover, histological assessment of ovarian tissue has led to a better understanding of
follicle distribution and architecture [11] and an understanding that primordial follicles survive and grow better in
vitro when maintained in an environment that mimics the ovarian cortex [13]. Perhaps most strikingly, we now
know that human follicles can grow in vitro to the large antral stage, can produce hormones and can complete
‘ovulation’ resulting in the generation of MII oocytes in vitro [15–17]. Additionally, a first-ever assessment of oocyte
changes with advanced maternal age showed that chromosome cohesion decreases and predates other indicators of
physiologic aging, similar to what has been demonstrated in studies in model organisms (mouse) [18]. These are
significant advances providing a prismatic view on human follicle maturation that could not have been done in any
other setting, and are providing the urgently needed fundamental new knowledge necessary to ensure that advances
are being made that will meet the needs of both current and future patients.
Clinical advancements
The NPC has undertaken various projects that reach across several diverse clinical disciplines with the ultimate
goal of better understanding the intricacies of the patient populations being served. We have highlighted important
clinical activities below that are most relevant to the oncology community.
Tamoxifen adherence
Tamoxifen initiation and persistence in reproductive-age estrogen receptor-positive breast cancer survivors is low,
with patients younger than 40 years at greatest risk for either discontinuing or being nonadherent to antiestrogen
treatment [19]. The underlying reasons for the poor utilization of this life-preserving treatment had not been well
investigated. An OC-supported study tested the hypothesis that fertility concerns may contribute to poor tamoxifen
use among premenopausal patients and found that, in a large young breast cancer patient cohort, fertility concerns
were statistically associated with both a failure to initiate tamoxifen treatment and with early discontinuation of
the drug [20]. In addition, expanded access to FP education prior to initial cancer therapy was important to help
increase long-term tamoxifen use as recommended by ASCO [21,22]. An international study is currently underway
to determine if temporary interruption of endocrine therapy to achieve a pregnancy will negatively impact breast
cancer outcomes [23]. The study also includes a psychooncological supplementary assessment of fertility concerns,
psychological well-being and decision-making. Importantly, a recent multicenter case–control study showed that
pregnancy after treatment for breast cancer, regardless of hormone receptor status, did not impact disease-free
survival when compared with nonpregnant patients. These findings were based on a median follow-up of 7.2 years
postpregnancy [24]. To this end, young breast cancer patients who have completed treatment, who are clinically
stable and express interest in becoming pregnant should be supported to reach this survivorship goal [25].
Good manufacturing practice
Globally, there is lack of standardization of freezing methodologies with centers performing both slow-freeze
or vitrification of reproductive tissues. Within the USA, there is growing interest in vitrification for OTC as
there are numerous reports of live births as a result of transplantation of vitrified ovarian tissue in Asia [26–28].
Domestically, products that are manufactured with the intent of receiving FDA approval for clinical use must be
produced under an FDA-approved investigational new drug application. Thus, the OC began generating a reliable
methodology and material list for an ovarian tissue vitrification kit and a supplementary warming and thawing
kit [29]. Kits were based on careful development of protocols with the expertise of cryobiologists, and manufactured
using good manufacturing practice requirements and good laboratory practice techniques and validated using
nonhuman primate ovarian tissue [30]. Discussion with industry partners is ongoing to move toward manufacture
and distribution of these kits for clinical use.
Provider knowledge & attitudes
To better understand clinician perspectives on FP and challenges in patient communication, a number of studies
were developed and implemented through the OC. A 2011 survey of pediatric oncology specialists found that
fertility threats are a major concern and found that specialists agreed that patients should be offered fertility
consultation [31]. However, only 46% of survey respondents indicated that they refer male pubertal patients over
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50% of the time, and only 12% of survey respondents reported referring female pubertal patients over 50% of
the time, indicating further education of providers is necessary [32]. A 2016 survey was distributed to physicians,
advanced practice nurses (APNs) and nurses within the field of pediatric oncology with special focus on adolescent
males. This study found that 93.6% of physicians, 74.6% of APNs and 48.2% of nurses discussed the impact
on fertility 76–100% of the time with their adolescent male patients. Physicians and APNs reported high levels
of comfort discussing fertility issues with their patients, with nurses feeling less comfortable. This study indicated
progress from the 2011 survey study, but supported the need of further education for providers, especially nurses,
to discuss fertility and FP with their patients and families [31].
Patient & family perspectives
To understand additional barriers that may impact fertility discussions, the OC completed multiple studies to
examine the decision-making process of parenthood goals among younger adolescents diagnosed with cancer. A
focus group was hosted of adult survivors of adolescent and young adult (AYA) cancer, ages 15–39 years at time of
diagnosis and their parents and found that while fertility was not recognized as a priority at the time of diagnosis,
it is a significant concern later in life [33]. A narrative review of adolescent decision-making in the oncology setting
was conducted to examine decisions related to cancer treatment, fertility concerns and capacity for decision-making
regarding life-threatening health issues. This review concluded adolescents had a strong desire to participate in
decisions about their cancer treatment and had significant fertility-related concerns [34]. A subsequent ethical
examination of a case of a parent who made a decision to preserve a very young child’s fertility on behalf of that
child concluded that parents should feel empowered to make such decisions on behalf of a child who is too young
to provide consent to maintain an open reproductive future for the child [35]. ASCO, ASRM and the American
Academy of Pediatrics and Children’s Oncology Group also support this endorsement [9,36,37].
Development of values clarification tools to address adolescent fertility knowledge
Consortium members adapted a version of the Wenzel reproductive concerns instrument to pilot test the Adolescent
Fertility Values Clarification Tool to better understand how adolescent girls felt about FP and future parenthood.
Results showed most parents did not accurately predict their daughter’s response and underestimated their daughter’s
level of concern about potential infertility [38]. The final tool contains an introduction to use, types of responses
typically seen among teen girls as fertility is discussed and how to address them, and frequently asked questions [31].
The development of this tool provided evidence that loss of fertility is a significant quality-of-life issue for female
teens and provides a rubric for discussions around this issue.
Adoption
The OC has addressed family-building challenges for patients who are diagnosed with infertility due to their disease
or treatment. Cancer survivors often face challenges when adopting as a result of real or perceived discrimination by
adoption agencies. Through an IRB-approved study, questionnaires were developed and distributed to 27 adoption
agencies in 21 states to examine perspectives on parenting postcancer [39]. The study found that agency perspectives
vary widely on whether cancer survivors should be allowed to adopt, with limited federal and state regulations
pertaining to adoption. Cancer survivors are encouraged to research a number of adoption agencies as they may find
the variation in policies to work in their favor on their journey to parenthood. The OC has developed a ‘Cancer
Friendly Adoption Agencies’ page on the OC website to assist cancer survivors.
Expansion of the OC & NPC mission
In 2012 and 2013, the European Society of Human Reproduction and Embryology and ASRM, respectively,
determined that egg banking was no longer experimental and was a safe and effective FP option for postpubertal
women [40]. At that time, the OC expanded its attention to providing FP options to additional patient populations:
pediatric girls, pediatric boys, patients with nonmalignant conditions, disorders of sex development (DSD) and
transgender individuals.
Pediatric girls
OTC remains the only FP option for prepubertal girls [41–43]. Using the adult protocol as a template, NPC
member institutions obtained IRB approval for OTC in pediatric patients. Pediatric oncologists partner with their
institutional reproductive endocrinology and infertility clinic or local fertility center for ovarian tissue freezing per
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Table 3. Number of patients with nonmalignant conditions enrolled in National Physicians Cooperative ovarian tissue
cryopreservation protocols from January 2007 to October 2017.
Diagnosis NPC OTC patients
Sickle cell anemia 17
Aplastic anemia 11
Beta thalassemia 9
Fanconi anemia 9
Turner syndrome 5
HLH 5
Myelodysplastic syndrome 4
Diamond–Blackfan anemia 2
Catamenial migraine 1
Combined immunity deficiency 1
Hurler’s syndrome 1
Interferon gamma deficiency 1
Systemic-onset juvenile idiopathic arthritis 1
Trisomy 8 myelodysplastic syndrome 1
Idiopathic hypereosinophilic syndrome 1
XO/XY mosaicism 1
HLH: Hemophagocytic lymphohistiocytosis; NPC OTC: National Physicians Cooperative ovarian tissue cryopreservation.
the OTC procedure. As OTC began expanding to pediatric centers, the median age of patients enrolling in OTC
protocols through the NPC has dropped from 30.6 years of age in 2007 to 12.4 years in 2017. Experimental
options that may be available in the future include heterotopic or orthotopic transplantation of ovarian tissue back
into the patient for restoration of reproductive or endocrine function, in vitro maturation of immature follicles
to obtain mature eggs for use in IVF, or use of ovarian bioprosthesis [15,17,44–46]. Each of these exciting options
highlight active areas of basic science research within the OC and NPC.
Pediatric boys & adult males
For adult males, the most common method of FP is sperm banking. For prepubertal boys, or AYA males unable to
provide a sperm sample, TTC may offer an option for restoring future fertility, similar to the use of OTC in the
female population. The TTC protocol and framework is available through the OC at the University of Pittsburgh
and serves as the coordinating center for other institutions interested in offering TTC to their patients. TTC has
not been used for spermatogenic recovery or pregnancy, but experimental options that may be available in the future
include transplantation of spermatogonial stem cells back into the patient’s testes, maturation of spermatozoa in
testicular tissue organ culture and testicular tissue autografting or xenografting [47–49]. Given this potential, seven
NPC member institutions have obtained IRB approval and enrolled a collective 108 patients.
Nonmalignant conditions, disorders of sex development, and gender dysphoria
NPC member institutions have the ability to expand their OTC eligibility to allow enrollment of patients with
nonmalignant conditions whose disease or treatment may cause infertility and between 2007 and October 2017, 70
such patients were enrolled (Table 3). DSD patients also face infertility due to various degrees of abnormal gonadal
development, while transgender patients potentially face infertility as a result of the treatments needed to fully
transition to another gender [42,50,51]. The Gender and Sex Diversity subcommittee of the NPC has mapped issues
faced by transgender and sex diverse patients to identify appropriate FP interventions, and address psychological
concerns and ethical considerations [52]. At the time of this publication, no NPC institutions offer OTC and TTC
to transgender patients; however, many sites are working with their institution to identify appropriate consent
and education strategies for this patient population, and involve the patient’s mental health provider during
their recommended assessment for medical intervention, as detailed by the World Professional Association for
Transgender Health and Endocrine Society clinical practice guidelines [53–56].
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Conclusion
The Oncofertility Consortium has created an infrastructure for sharing scientific and medical advances in a way that
enables patients access to the most up-to-date medical treatment plans and emerging reproductive technologies.
The NPC has effectively worked in a coordinated and strategic manner enabling better science, education and
medical applications to reach men, women and children to preserve their reproductive potential. Moving forward,
there is a need for long-term monitoring of technical advancements, including success rates, lab variability and
tissue utilization, however, there is currently no systematic data collection process in place within the USA. Data
collection is institution-specific and patient volumes at individual centers vary greatly. Additionally, due to the
experimental nature of OTC, there is currently no consensus on the best method to freeze and thaw ovarian tissue.
Further research is needed to develop best practices and streamlined protocols for mass utilization within the USA.
Future perspective
Cancer survivorship rates have steadily increased due to advances in early diagnosis and treatment. Unfortunately,
many AYA cancer survivors face reproductive dysfunction, including infertility, caused by the disease process
or cancer treatment and the potential for significant psychological distress due to infertility, which often leads
to adverse health outcomes and a poorer quality of life. The NPC has been involved in a number of OC-led
clinical studies investigating patient experiences, methods of service delivery and financial, ethical, legal or religious
considerations affecting the access of patients or providers to oncofertility services. Over the last decade, the NPC
has grown exponentially by geographic location, membership and in the number and types of patients served. The
original four core NPC member institutions were large academic hospital systems and treated adult female cancer
patients. Today, NPC member institutions include private IVF centers, community hospitals, pediatric hospitals
and standalone cancer centers, with participants from various clinical disciplines treating diverse populations of
pediatric and adult patients. Beyond the continental USA, Oncofertility Global Partner membership has rapidly
increased and OC materials have been translated into seven different languages. As the OC’s global reach has
expanded, relationships between Global Partner and NPC member institutions have developed organically through
collaborative research protocols, subcommittee participation and joint publications. In an effort to promote an
inclusive network and to further catalyze these connections, the OC will launch the Oncofertility Professional
Engagement Network (OPEN). OPEN will merge the NPC with the Global Partners Network and build upon the
solid foundation of each group by supporting a strong global network where members share resources, methodologies
and experiences, and foster significant collaboration among members. OPEN will continue the work of the valuable
NPC subcommittees, where highly engaged colleagues will meet, in person and virtually, to develop new research
protocols, identify best practices, and discuss challenges and pathways to success in specific focus areas. By merging
these powerful groups together, the OC will turn novel science into accessible end points for clinicians and patients
alike and provide a platform where concerns are raised, consensus is developed and patterns are identified at the
intersection of technology and application.
The field of Oncofertility is ever-evolving with new stakeholders and changing challenges. In an ideal world,
we would eliminate the need for our field. We can imagine this in a setting: where advances in cancer detection,
diagnosis and treatments eliminate cancer all together; where mitigation strategies exist to protect full fertility or
where interventional options exist to preserve full fertility; where FP is considered by all stakeholders (patients,
partners, providers, the public); and where FP is fully accessible to all. With the strength and determination of such
a field, we will ultimately achieve this ambitious vision.
However, in the immediate future there is still a critical need to advance patient needs in FP through the work of
integrated clinical and basic research teams. In the next few years, we will be seeking solutions to the oncofertility
problems of a diverse population of stakeholders – from the younger and younger pediatric population to the older
and older adult ones, to sex diverse individuals, to those with various types of infertility (iatrogenic, genetic, trauma)
and to those across a broad access grid with respect to education, geography, economic status, etc. We will consider
FP in contexts wider than we ever have. We will think about fertility needs across the anatomical spectrum from the
gonad to the reproductive tract to the nipple; we will expand endocrine support across the lifespan from puberty
and menstrual cyclicity to menopause and contraception; we will apply what we learn in humans to endangered and
threatened species to ensure a world of terrestrial diversity; we will meet transgenerational expectations; and we will
imagine ways to reproduce in new territories beyond earth and ways that transcend our bodies with reproductive
bioprosthetics. All the while, we will do so in a manner that enables autonomous and error-free reproduction and
will be cognizant of whose interest, under what auspices and for what purposes we do so.
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Executive summary
• Adolescents have a strong desire to participate in their cancer treatment and have significant fertility-related
concerns.
• The Oncofertility Consortium (OC) has created an infrastructure for sharing scientific and medical advances in a
way that enables patients to access to the most up-to-date medical treatment plans and emerging reproductive
technologies.
• The National Physicians Cooperative (NPC) is a nationwide network of member institutions dedicated to
preserving the fertility of their patients.
• The NPC has worked in a coordinated and strategic manner enabling better science, education and medical
applications to reach men, women and children to preserve their reproductive potential.
• Individual participants at NPC member institutions are the direct points of contact with patients and many are
leaders in translational research.
• Physicians and advanced practice nurses have a high comfort level in discussing fertility issues with patients while
further education is needed for providers, especially nurses, to assist with fertility and FP discussions with patients
and their families.
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